Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2013 3
2014 8
2015 6
2016 2
2017 2
2018 1
2019 4
2020 3
2021 4
2022 10
2023 9
2024 10
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Yarur AJ, Deepak P. Yarur AJ, et al. Gastroenterology. 2024 Feb;166(2):357-358. doi: 10.1053/j.gastro.2023.11.013. Epub 2023 Nov 11. Gastroenterology. 2024. PMID: 37952900 No abstract available.
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Papamichael K, et al. Among authors: yarur aj. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185. doi: 10.1016/S2468-1253(21)00223-5. Lancet Gastroenterol Hepatol. 2022. PMID: 35026171 Free PMC article. Review.
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV Jr, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. Cheifetz AS, et al. Among authors: yarur aj. Am J Gastroenterol. 2021 Oct 1;116(10):2014-2025. doi: 10.14309/ajg.0000000000001396. Am J Gastroenterol. 2021. PMID: 34388143 Free PMC article. Review.
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, Wolf DC, Ritter T, Schreiber S, Woolcott JC, Modesto I, Keating M, Shan K, Wu J, Chiorean MV, Baert F, Dubinsky MC, Goetsch M, Danese S, Feagan BG. Vermeire S, et al. Among authors: yarur aj. J Crohns Colitis. 2024 Nov 4;18(11):1780-1794. doi: 10.1093/ecco-jcc/jjae079. J Crohns Colitis. 2024. PMID: 38877972 Free PMC article. Clinical Trial.
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S. Peyrin-Biroulet L, et al. Among authors: yarur aj. J Crohns Colitis. 2024 Aug 14;18(8):1270-1282. doi: 10.1093/ecco-jcc/jjae038. J Crohns Colitis. 2024. PMID: 38613425 Free PMC article. Clinical Trial.
Response to Bourgonje and Mian.
Yarur AJ. Yarur AJ. Am J Gastroenterol. 2023 Dec 1;118(12):2309-2310. doi: 10.14309/ajg.0000000000002449. Am J Gastroenterol. 2023. PMID: 38033232 No abstract available.
A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease.
Johnson AM, Askar M, Belani S, Khan A, Xu AA, Kassmeyer B, Said H, Santiago-Castro M, Devi J, Huang K, Jaiprada F, Seth N, Dulaney D, Loftus EV Jr, Fenster M, Patel A, Bishu S, Ungaro RC, Shukla R, Yarur AJ, Deepak P. Johnson AM, et al. Among authors: yarur aj. J Crohns Colitis. 2025 May 8;19(5):jjaf070. doi: 10.1093/ecco-jcc/jjaf070. J Crohns Colitis. 2025. PMID: 40289770
Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: A Multicenter Study.
Devi J, Xu A, Stone M, Patel A, Khan A, Reddy N, Klein J, Chowla N, Benson C, Luu BC, Huang K, Jaiprada F, Fenster M, Ungaro R, Pekow J, Johnson AM, Yarur AJ, Shukla R, Huecker J, Bishu S; REBOOT IBD Consortium; Deepak P. Devi J, et al. Among authors: yarur aj. Clin Gastroenterol Hepatol. 2025 Nov;23(12):2281-2291.e4. doi: 10.1016/j.cgh.2025.01.012. Epub 2025 Mar 8. Clin Gastroenterol Hepatol. 2025. PMID: 40058746 Free article.
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG. Danese S, et al. Among authors: yarur aj. Lancet Gastroenterol Hepatol. 2025 Oct;10(10):882-895. doi: 10.1016/S2468-1253(25)00129-3. Epub 2025 Jul 21. Lancet Gastroenterol Hepatol. 2025. PMID: 40706613 Clinical Trial.
70 results